Abstract GS3-06: Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) +/- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2−positive locally recurrent/metastatic breast cancer (LR/mBC)

10.1158/0008-5472.sabcs11-s4-8 ◽

2011 ◽

Cited By ~ 19

Author(s):

L Gianni ◽

G Romieu ◽

M Lichinitser ◽

S Serrano ◽

M Mansutti ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

First Results ◽

Locally Recurrent

Download Full-text

CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-paclitaxel (NP) or ixabepilone (Ix) with or without bevacizumab (B) as first-line therapy for locally recurrent or metastatic breast cancer (MBC).

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.cra1002 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. CRA1002-CRA1002 ◽

Cited By ~ 12

Author(s):

Hope S. Rugo ◽

William Thomas Barry ◽

Alvaro Moreno-Aspitia ◽

Alan P. Lyss ◽

Constance Cirrincione ◽

...

Keyword(s):

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Daily News ◽

Phase Iii Trial ◽

Online Supplement ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Final Text

CRA1002 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Monday, June 4, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Monday edition of ASCO Daily News.

Download Full-text

Faculty Opinions recommendation of AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717998592.793477025 ◽

2013 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Her2 Positive ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent

Download Full-text

A randomized phase III trial of paclitaxel with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: Eastern cooperative oncology group trial E2100

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(06)80030-3 ◽

2006 ◽

Vol 4 (2) ◽

pp. 47 ◽

Cited By ~ 5

Author(s):

R. Zon ◽

Miller ◽

M. Wang ◽

J. Gralow ◽

M. Dickler ◽

...

Keyword(s):

Eastern Cooperative Oncology Group ◽

Metastatic Breast ◽

Phase Iii ◽

Oncology Group ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy ◽

Locally Recurrent ◽

Group Trial

Download Full-text

Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.7542 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 7542-7542 ◽

Cited By ~ 2

Author(s):

Jonathan W. Friedberg ◽

Andres Forero-Torres ◽

Beata Holkova ◽

Jerome H. Goldschmidt ◽

Ralph V. Boccia ◽

...

Keyword(s):

Elderly Patients ◽

Hodgkin Lymphoma ◽

Brentuximab Vedotin ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Long Term Follow Up

Download Full-text

Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.lba1011 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. LBA1011-LBA1011 ◽

Cited By ~ 87

Author(s):

D. Miles ◽

A. Chan ◽

G. Romieu ◽

L. Y. Dirix ◽

J. Cortes ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iii Study ◽

Locally Recurrent

Download Full-text

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

European Journal of Cancer ◽

10.1016/j.ejca.2016.09.024 ◽

2017 ◽

Vol 70 ◽

pp. 146-155 ◽

Cited By ~ 60

Author(s):

David Miles ◽

David Cameron ◽

Igor Bondarenko ◽

Lyudmila Manzyuk ◽

Juan Carlos Alcedo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

First Line Therapy ◽

Line Therapy ◽

Biomarker Evaluation

Download Full-text

Sonography and Clinical Outcome of Viable Hydatid Liver Cysts Treated With Double Percutaneous Aspiration and Ethanol Injection as First-Line Therapy: Efficacy and Long-Term Follow-Up

American Journal of Roentgenology ◽

10.2214/ajr.08.1518 ◽

2009 ◽

Vol 193 (3) ◽

pp. W186-W192 ◽

Cited By ~ 22

Author(s):

Antonio Giorgio ◽

Antonella Di Sarno ◽

Giorgio de Stefano ◽

Giulia Liorre ◽

Nunzia Farella ◽

...

Keyword(s):

First Line ◽

Percutaneous Aspiration ◽

Ethanol Injection ◽

Liver Cysts ◽

Therapy Efficacy ◽

First Line Therapy ◽

Line Therapy ◽

Long Term Follow Up

Download Full-text

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

Annals of Oncology ◽

10.1093/annonc/mdh393 ◽

2004 ◽

Vol 15 (10) ◽

pp. 1527-1534 ◽

Cited By ~ 100

Author(s):

S. Chan ◽

N. Davidson ◽

E. Juozaityte ◽

F. Erdkamp ◽

A. Pluzanska ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Liposomal Doxorubicin ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Epirubicin and cyclophosphamide versus epirubicin and docetaxel as first-line therapy for women with metastatic breast cancer: final results of a randomised phase III trial

Annals of Oncology ◽

10.1093/annonc/mdp585 ◽

2010 ◽

Vol 21 (7) ◽

pp. 1430-1435 ◽

Cited By ~ 13

Author(s):

J.-U. Blohmer ◽

P. Schmid ◽

J. Hilfrich ◽

K. Friese ◽

A. Kleine-Tebbe ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

First Line Therapy ◽

Line Therapy

Download Full-text